YAP1 and adenocarcinoma: For example, examination of non-small cell lung cancer (NSCLC), which includes adenocarcinoma, has revealed that roughly 70% of cases are associated with visibly elevated levels and/or nuclear localization of YAP or TAZ, and that elevated expression of YAP/TAZ correlates with poor prognosis [12–18].